Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children
-
Published:2023-12-08
Issue:1
Volume:20
Page:11-25
-
ISSN:1708-8569
-
Container-title:World Journal of Pediatrics
-
language:en
-
Short-container-title:World J Pediatr
Author:
Zhang Xian-Li,Zhang Xi,Hua Wang,Xie Zheng-De,Liu Han-Min,Zhang Hai-Lin,Chen Bi-Quan,Chen Yuan,Sun Xin,Xu Yi,Shu Sai-Nan,Zhao Shun-Ying,Shang Yun-Xiao,Cao Ling,Jia Yan-Hui,Lin Luo-Na,Li Jiong,Hao Chuang-Li,Dong Xiao-Yan,Lin Dao-Jiong,Xu Hong-Mei,Zhao De-Yu,Zeng Mei,Chen Zhi-Min,Huang Li-Su
Abstract
Abstract
Background
Respiratory syncytial virus (RSV) is the leading global cause of respiratory infections and is responsible for about 3 million hospitalizations and more than 100,000 deaths annually in children younger than 5 years, representing a major global healthcare burden. There is a great unmet need for new agents and universal strategies to prevent RSV infections in early life. A multidisciplinary consensus development group comprising experts in epidemiology, infectious diseases, respiratory medicine, and methodology aims to develop the current consensus to address clinical issues of RSV infections in children.
Data sources
The evidence searches and reviews were conducted using electronic databases, including PubMed, Embase, Web of Science, and the Cochrane Library, using variations in terms for “respiratory syncytial virus”, “RSV”, “lower respiratory tract infection”, “bronchiolitis”, “acute”, “viral pneumonia”, “neonatal”, “infant” “children”, and “pediatric”.
Results
Evidence-based recommendations regarding diagnosis, treatment, and prevention were proposed with a high degree of consensus. Although supportive care remains the cornerstone for the management of RSV infections, new monoclonal antibodies, vaccines, drug therapies, and viral surveillance techniques are being rolled out.
Conclusions
This consensus, based on international and national scientific evidence, reinforces the current recommendations and integrates the recent advances for optimal care and prevention of RSV infections. Further improvements in the management of RSV infections will require generating the highest quality of evidence through rigorously designed studies that possess little bias and sufficient capacity to identify clinically meaningful end points.
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology and Child Health
Reference162 articles.
1. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. The Lancet. 2022;399:2047–64. 2. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. The Lancet. 2017;390:946–58. 3. Bardsley M, Morbey RA, Hughes HE, Beck CR, Watson CH, Zhao H, et al. Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis. 2023;23:56–66. 4. Williams TC, Sinha I, Barr IG, Zambon M. Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2021;26:2100186. 5. Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics. 2021;148:e2021052089.
|
|